Development and Validation of a Prognostic Prediction Model for Postoperative Ovarian Sex Cord-Stromal Tumor Patients

Danming You*  
CDE 1  Zuyu Zhang*  
AG 2  Mingzhu Cao

* Danming You and Zuyu Zhang contributed equally in this article

Corresponding Author:  
Mingzhu Cao, e-mail: 2019683081@gzhmu.edu.cn

Source of support:  
This work was supported by the National Natural Science Foundation of China (grant no. 81701400) and the Natural Science Foundation of Guangdong Province (grant no. 2017A030310447)

Background:  
We developed a nomogram for prognostic prediction of overall survival (OS) in postoperative ovarian sex cord-stromal tumor (SCST) patients and discuss the effect of chemotherapy at various FIGO stages.

Material/Methods:  
SCST patients after surgery from 2004 to 2015 were enrolled from the Surveillance, Epidemiology and End-Results (SEER) database, matched into pairs by propensity score matching (PSM), and divided into a training set and a validation set. Univariate and multivariate Cox analyses were conducted to identify significant variables for the development of the nomogram. The nomogram model was validated by concordance index (C-index), receiver operating characteristics (ROCs) curve, calibration plot, and decision curve analysis (DCA). Survival curves showed the integrative ability of prognostic prediction and the efficacy of chemotherapy.

Results:  
A total of 913 SCST patients were initially enrolled, and after PSM, 506 patients were included. Age, marital status, CA125 levels, tumor size, FIGO stage, grade, and chemotherapy were indicators for building the OS nomogram. The C-index was 0.850 in the training set and 0.786 in the validation set. Calibration plots were satisfactory and the nomogram had relatively better clinical utility than FIGO stage. The survival analysis showed that the low-risk group had generally longer survival than the high-risk group based on the prognostic score, and chemotherapy had an overall reverse effect on OS.

Conclusions:  
The nomogram model displays the potential to provide individualized prognosis probability of SCSTs and to aid in clinical decision-making. The unfavorable results of chemotherapy in all stages shows the need for further exploration.

MeSH Keywords:  
Chemotherapy, Adjuvant • Nomograms • Prognosis • SEER Program • Sex Cord-Gonadal Stromal Tumors

Full-text PDF:  
https://www.medscimonit.com/abstract/index/idArt/925844
Background

Ovarian sex cord-stromal tumors (SCSTs) are rare ovarian tu-
mors derived from sex cords and ovarian stroma or mesen-
chyme [1], accounting for approximately 7% of ovarian tumors,
and the incidence rate is 2.1 per million women [2]. Sex cord-
stromal tumors contain various histologic subtypes, mainly
granulosa cell tumors (GCTs), Sertoli-Leydig cell tumors, theco-
as, and gynandroblastomas, with GCTs accounting for nearly
90% of the malignancies [3]. SCSTs are mostly found in adults,
including many perimenopausal and postmenopausal women.
Although most cases present slow growth and good progno-
sis, about 20% relapse or metastasize, which can be fatal [4].
It was recently reported that mutations in FOXL2 are ubiqui-
tous in adult GCTs, and DICER1 mutations are typically found
in Sertoli-Leydig cell tumors, which could be potential thera-
peutic targets [5].

Debulking surgery, regardless of the cancer process, is always
the most effective treatment for sex cord-stromal tumors [6].
Most SCSTs patients are diagnosed at an early stage for which
no evidence supports postoperative adjuvant treatment due
to the low risk of recurrence [7]. However, some researchers
suggest chemotherapy be used after surgery for FIGO stage IC
patients with larger tumor size or high mitotic index [8]. The
small number of advanced patients makes it difficult to draw
a firm conclusion, but the current clinical consensus is that
adjuvant chemotherapy should be reserved for stage II–IV pa-
tients [6]. Therefore, whether chemotherapy is effective for
patients at different stages remains controversial. Hormonal
therapy is another reasonable treatment for advanced GCTs
due to their dependence on estrogen, but at present no val-
id data support the effect of hormone treatment in the post-
operative setting [9].

Prognostic prediction has been impeded by the rarity of pa-
tients and multiplicity of histologic and biologic behaviors [1].
International Federation of Gynecology and Obstetrics (FIGO)
stage, age, tumor size, and absence of residual disease have
been reported to be prognostic factors [10]. However, to the
best of our knowledge, there has been no research on inte-
grating the prediction model of SCSTs; therefore, individualized
survival forecasting is imperative. In this study, we evaluated
the prognostic value of chemotherapy in SCST patients based
on the Surveillance, Epidemiology, and End-Results (SEER) da-
tabase and established and validated a predictive nomogram
incorporating chemotherapy and other clinically significant fac-
tors. We also compared the clinical performance of our nomo-
gram with the FIGO staging system. We hypothesized that the
prediction model developed in this study has better predictive
value than the FIGO staging system. This research may pro-
vide valuable evidence for clinical decision-making, especial-
ly regarding chemotherapy.

Material and Methods

Patients and study design

The data of patients diagnosed as having SCST were obtained
from the Surveillance, Epidemiology, and End-Results (SEER) 18
registry database (http://seer.cancer.gov) using SEERStar 8.3.6
software. The SEER database was established by the National
Cancer Institute and collects data on patient, disease, and sur-
vival outcomes, covering [11] nearly 35% of the US population.
We initially retrieved a total of 70 225 individuals diagnosed with
ovarian cancer from 2004 to 2015, with the site code “C56.9”
according to the International classification of Diseases for
Oncology, Third Edition (ICD-O-3). Morphology codes “8590/3-
8671/3” were used to identify the malignant sex cord-stromal
tumors. Treatment for stage IV patients varies between indivi-
duals and is not suitable for systematic analysis [12]. The in-
clusion criteria were as follows: (1) patients with confirmed I,
II, or III FIGO stage determined by American Joint Committee
on Cancer (AJCC); (2) patients with complete survival informa-
tion including vital status, survival time, and cause of death; (3)
patients who underwent surgery on the primary site; and (4)
patients with positive histology. The exclusion criteria were as
follows: (1) patients who underwent radiotherapy; and (2) sur-
gery of primary site is tumor destruction, with no or unknown
pathologic specimen. Finally, a total of 913 patients were in-
cluded in our study (Figure 1). For data analysis, patients were
grouped into 2 groups ≤50 years old and >50 years old based
on the median age of the overall population. Tumor grade was
classified into well differentiated (G1), moderately differen-
tiated (G2), poorly differentiated (G3), undifferentiated (G4),
and an unknown group. The maximum diameter of the tumor
was used as tumor size, and was determined during surgery.
Tumor size was divided into 3 subgroups by median value of
95 mm and an unknown group. Blood or serum CA125 levels
were recorded before surgery, and the reference value was be-
low 35 μg/ml. The histology types were simply divided as gran-
ulosa cell tumors (8620–8622) and non-granulosa cell tumors
(8590, 8593, 8600, 8623, 8631, 8634, 8640, 8650, 8670) based
on the pathological reports. The race included white, black,
others (Asian, Pacific Islander, American Indian, and Alaska
Native), or unknown. The marital status included married, un-
married (‘single’, ‘separated’, ‘divorced’ and ‘widowed’), and
unknown. The primary outcome was overall survival (OS), and
survival time was defined as the time from diagnosis to death
from any cause. This study followed the recommendations of
the Transparent Reporting of a multivariable prediction model
for Individual Prognosis Or Diagnosis (TRIPOD) statement [13].

Propensity score matching

To better assess the prognostic effect of chemotherapy, we per-
formed propensity score matching (PSM) to reduce selection
We assessed model performance by testing discrimination and calibration. Concordance index (C-index) and receiver operating characteristic (ROC) curves were utilized to determine the discrimination and predictive ability. Calibration plots graphically estimate the agreement between actual and predicted outcome probabilities, where a slope close to 1 indicates a well-calibrated predictor [15]. Bootstrapping with 1000 resamples was used to adjust for bias.

### Survival analysis

Based on the median cut-off value of the prognostic index (212 points), the study population was divided into low-risk (<212 points) and high-risk (≥212 points) groups. Kaplan-Meier analysis was used to estimate the survival of patients in FIGO stage I, II, and III and overall population. The log-rank test was used to assess statistically significant differences between low- and high-risk groups.

### Clinical performance

Decision curve analysis (DCA) was used to evaluate and compare the clinical usefulness of the nomogram [16]. DCA was carried out to assess the clinical benefit of the new nomogram in comparison with the FIGO staging system in the training and validation set and in the overall study population. The DCA was performed using R package ‘Tableone’ and ‘Nonrandom’.

## Results

### Patients’ baseline characteristics before and after propensity score matching

#### Before PSM

In total, 913 eligible SCST patients diagnosed from 2004 to 2015 in the SEER database were enrolled in the study. Patients’ baseline characteristics before and after propensity score matching are summarized in Table 1. In the overall patients, the median age was 50 years old (range, 6–91 years). Patients were divided into binary groups according to whether they have received chemotherapy. The median follow-up time of patients was 50 (range, 3–154) months and 67 (range: 0–155) months in the chemotherapy and non-chemotherapy group, respectively. There were significant differences in age (P=0.001), grade (P<0.001), histology (P<0.001), marital status (P=0.013), FIGO stage (P<0.001), tumor size (P<0.001), and CA125 levels (P<0.001) between the 2 groups. Patients who underwent chemotherapy after surgery on primary sites had a larger proportion of characteristics such as poorly differentiated and non-chemotherapy.
Table 1. Correlations between chemotherapy and baseline characteristics of patients with sex cord-stromal tumors in the overall included population and propensity score-matched population.

| Characteristic       | Before PSM | After PSM | p-Value | Before PSM | After PSM | p-Value |
|----------------------|------------|-----------|---------|------------|-----------|---------|
| Number of patients   | 644        | 269       | 253     | 253        |           |         |
| Age (years)          |            |           |         |            |           |         |
| ≤50                  | 314 (48.8) | 165 (61.3)| 144 (56.9)| 150 (59.3)|         |
| >50                  | 330 (51.2) | 104 (38.7)| 109 (43.1)| 103 (40.7)|         |
| Race                 |            |           |         |            |           |         |
| White                | 437 (67.9) | 187 (69.5)| 175 (69.2)| 179 (70.8)|         |
| Black                | 149 (23.1) | 60 (22.3)| 45 (17.8)| 56 (22.1)|         |
| Others and unknown   | 58 (9.0)   | 22 (8.2) | 33 (13.0)| 18 (7.1)  |         |
| Marital status       |            |           |         |            |           |         |
| Married              | 282 (43.8) | 131 (48.7)| 108 (42.7)| 121 (47.8)|         |
| Unmarried            | 321 (49.8) | 133 (49.4)| 136 (53.8)| 127 (50.2)|         |
| Unknown              | 41 (6.4)   | 5 (1.9)  | 9 (3.6)  | 5 (2.0)   |         |
| CA125 status         |            |           |         |            |           |         |
| Negative/normal      | 192 (29.8) | 80 (29.7)| 75 (29.6)| 70 (27.7)|         |
| Positive/elevated    | 116 (18.0) | 85 (31.6)| 58 (22.9)| 81 (32.0)|         |
| Borderline or unknown| 336 (52.2) | 104 (38.7)| 120 (47.4)| 102 (40.3)|         |
| Tumor size (mm)      |            |           |         |            |           |         |
| ≤95                  | 311 (48.3) | 86 (32.0)| 80 (31.6)| 82 (32.4)|         |
| >95                  | 253 (39.3) | 146 (54.3)| 131 (51.8)| 143 (56.5)|         |
| Unknown              | 80 (12.4)  | 37 (13.8)| 42 (16.6)| 28 (11.1)|         |
| FIGO stage           |            |           |         |            |           |         |
| I                    | 566 (87.9) | 152 (56.5)| 180 (71.1)| 150 (59.3)|         |
| II                   | 39 (6.1)   | 68 (25.3)| 34 (13.4)| 63 (24.9)|         |
| III                  | 39 (6.1)   | 49 (18.2)| 39 (15.4)| 40 (15.8)|         |
| Grade                |            |           |         |            |           |         |
| Well differentiated and moderately differentiated | 113 (17.5) | 41 (15.2)| 38 (15.0)| 38 (15.0)|         |
| Poorly differentiated and undifferentiated | 62 (9.6) | 57 (21.2)| 48 (19.0)| 56 (22.1)|         |
| Unknown               | 469 (72.8) | 171 (63.6)| 167 (66.0)| 159 (62.8)|         |
| Histology             |            |           |         |            |           |         |
| Granulosa            | 566 (87.9) | 194 (72.1)| 177 (70.0)| 183 (72.3)|         |
| Non-granulosa        | 78 (12.1)  | 75 (27.9)| 76 (30.0)| 70 (27.7)|         |

Non-granulosa includes Sertoli-Leydig cell tumor (n=94), Sertoli cell tumor (n=7), Leydig cell tumor (n=3), steroid cell tumor (n=21), thecoma (n=4), and sex cord-stromal NOS, not otherwise specified (n=24). Surg only, patients underwent surgery and did not or unknown if received chemotherapy. Surg+Chem, patients underwent surgery and received chemotherapy.
Table 2. Patients demographics and clinicopathological characteristics of training set and validation set.

| Factors                        | Training set | Validation set |
|-------------------------------|--------------|----------------|
| **Number of patients**        | 356          | 150            |
| **Age (years)**               |              |                |
| ≤50                           | 214 (60.11%) | 80 (53.33%)    |
| >50                           | 142 (39.89%) | 70 (46.67%)    |
| **Race**                      |              |                |
| White                         | 254 (71.35%) | 100 (66.67%)   |
| Black                         | 64 (17.98%)  | 37 (24.67%)    |
| Others and unknown            | 38 (10.67%)  | 13 (8.67%)     |
| **Marital status**            |              |                |
| Married                       | 157 (44.10%) | 72 (48.00%)    |
| Unmarried                     | 188 (52.81%) | 75 (50.00%)    |
| Unknown                       | 11 (3.09%)   | 3 (2.00%)      |
| **CA125 status**              |              |                |
| Negative/normal               | 93 (26.12%)  | 52 (34.67%)    |
| Positive/elevated             | 102 (28.65%) | 37 (24.67%)    |
| Borderline or unknown         | 161 (45.22%) | 61 (40.67%)    |
| **Tumor size (mm)**           |              |                |
| ≤95                           | 115 (32.30%) | 47 (31.33%)    |
| >95                           | 194 (54.49%) | 80 (53.33%)    |
| Unknown                       | 47 (13.20%)  | 23 (15.33%)    |
| **FIGO stage**                |              |                |
| I                             | 227 (63.76%) | 103 (68.67%)   |
| II                            | 65 (18.26%)  | 32 (21.33%)    |
| III                           | 64 (17.98%)  | 15 (10.00%)    |
| **Grade**                     |              |                |
| Well differentiated and moderately differentiated | 51 (14.33%) | 25 (16.67%)    |
| Poorly differentiated and undifferentiated | 37 (20.79%) | 30 (20.00%)    |
| Unknown                       | 231 (64.89%) | 95 (63.33%)    |
| **Histology**                 |              |                |
| Granulosa                     | 260 (73.03%) | 100 (66.67%)   |
| Non-granulosa                 | 96 (26.97%)  | 50 (33.33%)    |
| **Chemotherapy**              |              |                |
| No/unknown                    | 181 (50.84%) | 72 (48.00%)    |
| Yes                           | 175 (49.16%) | 78 (52.00%)    |
| **Survival months**           |              |                |
| Alive                         | 302 (84.83%) | 124 (82.67%)   |
| Dead                          | 54 (15.17%)  | 26 (17.33%)    |
| **Overall survival**          |              |                |
undifferentiated, non-granulosa histology type, advanced FIGO stage, larger tumor size, and elevated CA125 levels. Table 1 displays the demographic and clinicopathologic characteristics of the 913 patients.

**After PSM**

Propensity score matching (1:1) between the chemotherapy and non-chemotherapy groups was performed. After matching, 253 matched pairs were obtained. The median survival was 59 months (range, 0–154 months). The median follow-up time of patients was 52 (range, 3–154) months and 67 (range, 0–154) months in the chemotherapy and non-chemotherapy groups, respectively. FIGO stage was significantly different (P=0.003) between the 2 groups, while the other variables were not (Table 1). Then, the matched population were randomly divided into a training set (n=356) and a validation set (n=150). The baseline characteristics of the 2 groups are shown in Table 2.

**Univariate and multivariate analysis**

Univariate and multivariate analyses were carried out using the Cox proportional hazard model on the training set to explore the predicted variables (Table 3). To include sufficiently meaningful indicators, variables with P>0.10 were taken forward to multivariate analysis. Eventually, variables with P<0.05 in multivariate analysis were used as independent predictors of patient prognosis. The multivariate analyses revealed that chemotherapy worsened the OS (HR=1.86, CI=1.05–3.29, P=0.034). Older age (>50 years) (HR=3.49, 95% CI=1.93–6.30), advanced FIGO stage (stage II, HR=2.82, 95% CI=1.35–5.88 and stage III, HR=6.79, 95% CI=3.42–13.47), and positive CA125 levels (HR=6.94, 95% CI=2.35–20.50) were the most significant risk factors for OS (P<0.001). Tumor grade did not meet the requirement in univariate analysis (HR=2.32, 95% CI=0.76–7.13, P=0.14), whereas tumor grade was usually considered important for survival prediction and therefore was included in the multivariate analysis (HR=3.34, 95% CI=1.04–10.79, P=0.043). Unmarried status was also a risk factor for poor prognosis (HR=2.04, P=0.027). However, histology type had no effect on overall survival in the univariate analysis (HR=1.19, 95% CI=0.67–2.12, P=0.553) and race was not related to OS in the multivariate analysis.

**Nomogram development**

Age, grade, marital status, FIGO stage, chemotherapy, tumor size, and CA 125 levels were significantly associated with OS. The nomogram for predicting 1-, 3-, and 5-year OS was developed by incorporating these 7 independent prognostic factors (Figure 2). Each variable had a corresponding score in the nomogram (Table 3). For instance, a 55-year-old (63 points) divorced woman (34 points) underwent ovarian surgery for a 9-cm sex cord-stromal tumor (0 point). The preoperative CA125 was 35 ug/ml (60 points). Postoperative tumor grading was III (64 points) and staging was FIGO III (98 points). She received chemotherapy after surgery (34 points). In this case, there were 353 total points, and the predicted 3- and 5-year survival rates were approximately 45% and 40%. The nomogram indicated that FIGO stage and CA125 levels contributed most to the outcome, followed by grade, tumor size, and age.

**Nomogram validation**

The C-indexes in the nomogram and FIGO staging system in the training set, validation set, and overall study population are listed in Table 4. The C-index for the OS prediction nomogram was 0.850 (95% CI=0.805–0.895) for the training group, 0.786 (95% CI=0.696–0.876) for the validation group, and 0.768 (95% CI=0.717–0.819) for the overall population, which were all higher than the corresponding C-indexes for the FIGO stage. ROC curves of the nomogram and FIGO stage for 1-, 3-, and 5-year OS also indicated that the nomogram had more accurate predictive and discriminative abilities than FIGO stage (Figure 3). The calibration curves demonstrated good agreement between the nomogram-predicted OS probability and the actual OS probability in both the training set and validation set (Figure 4A, 4B), indicating the reliability of our nomogram.

**Survival analysis**

Combining multiple prognostic predictors into a single score improves model assessment. The prognostic index of every patient was calculated according to each variable score, and the patients were divided into high-risk and low-risk groups using the median prognostic index (212 points) as the cut-off value. The overall survival time of the high-risk group was significantly shorter than that of the low-risk group in overall population (P<0.001), FIGO stage I patients (P<0.001), and FIGO stage III patients (P=0.041), proving the integral predictive capacity of the novel model. PI had a less significant function in FIGO stage II (P=0.081), probably due to the small population of patients included in this stage (Figure 5A). Chemotherapy showed a significantly worse effect in multivariate analysis of the matched population. To explore its function in different tumor stages, survival analyses based on FIGO stage I, II, and III patients were conducted. Chemotherapy showed a trend that approached significance in the overall population (P=0.067) and stage I (P=0.11) patients, but there was no effect on OS in stage II (P=0.95) and III (P=0.68) patients (Figure 5B). In stages IA and IB, in which chemotherapy is not recommended after surgery, patients who underwent postoperative chemotherapy had worse OS than those who did not (P=0.031). In stage IC, in which use of chemotherapy is controversial, the OS presented no significant difference (P=0.7) (Figure 5C).
Table 3. Univariate and multivariate analysis for the training set.

| Factors               | Univariate analysis | Multivariate analysis | Score |
|-----------------------|---------------------|-----------------------|-------|
|                       | HR                  | 95% CI                | P*    | HR                  | 95% CI                | P**   |       |
| **Age (years)**       |                     |                       |       |                     |                       |       |       |
| £50                   | Ref                 |                       |       | Ref                 |                       |       | 0     |
| >50                   | 3.09                | (1.76–5.40)           | <0.0001 | 3.49                | (1.93–6.30)           | <0.0001 | 63    |
| **Race**              |                     |                       |       |                     |                       |       |       |
| White                 | Ref                 |                       |       | Ref                 |                       |       | 0     |
| Black                 | 0.77                | (0.38–1.58)           | 0.4821 | 0.50                | (0.24–1.07)           | 0.0732 |       |
| Others and unknown    | 0.15                | (0.02–1.07)           | 0.0581 | 0.17                | (0.02–1.30)           | 0.0886 |       |
| **Marital status**    |                     |                       |       |                     |                       |       |       |
| Married               | Ref                 |                       |       | Ref                 |                       |       | 0     |
| Unmarried             | 2.22                | (1.22–4.05)           | 0.0092 | 2.04                | (1.08–3.85)           | 0.0273 | 34    |
| Unknown               | 1.74                | (0.40–7.63)           | 0.4604 | 1.64                | (0.35–7.76)           | 0.5344 | 19    |
| **CA12S status**      |                     |                       |       |                     |                       |       |       |
| Negative/normal       | Ref                 |                       |       | Ref                 |                       |       | 0     |
| Positive/elevated     | 7.86                | (2.75–22.41)          | 0.0001 | 6.94                | (2.35–20.50)          | 0.0005 | 100   |
| Borderline or unknown | 3.23                | (1.11–9.38)           | 0.0309 | 2.79                | (0.95–8.19)           | 0.0625 | 60    |
| **Tumor size (mm)**   |                     |                       |       |                     |                       |       |       |
| £95                   | Ref                 |                       |       | Ref                 |                       |       | 0     |
| >95                   | 5.06                | (1.99–12.85)          | 0.0007 | 2.22                | (0.83–5.92)           | 0.1123 | 43    |
| Unknown               | 5.38                | (1.87–15.48)          | 0.0018 | 3.36                | (1.14–9.87)           | 0.0275 | 63    |
| **FIGO stage**        |                     |                       |       |                     |                       |       |       |
| I                     | Ref                 |                       |       | Ref                 |                       |       | 0     |
| II                    | 3.28                | (1.64–6.57)           | 0.0008 | 2.82                | (1.35–5.88)           | 0.0059 | 58    |
| III                   | 5.20                | (2.76–9.79)           | <0.0001 | 6.79                | (3.42–13.47)          | <0.0001 | 98    |
| **Grade**             |                     |                       |       |                     |                       |       |       |
| Well differentiated and moderately differentiated | Ref |                       |       | Ref                 |                       |       | 0     |
| Poorly differentiated and undifferentiated | 2.32 | (0.76–7.13) | 0.1403 | 3.34 | (1.04–10.79) | 0.0434 | 64    |
| Unknown               | 2.22                | (0.79–6.23)           | 0.1299 | 2.08                | (0.72–6.04)           | 0.1781 | 36    |
| **Histology**         |                     |                       |       |                     |                       |       |       |
| Granulosa             | Ref                 |                       |       | Ref                 |                       |       | 0     |
| Non-granulosa         | 1.19                | (0.67–2.12)           | 0.5526 |       |                     |       |       |
| **Chemotherapy**      |                     |                       |       |                     |                       |       |       |
| No/unknown            | Ref                 |                       |       | Ref                 |                       |       | 0     |
| Yes                   | 1.59                | (0.93–2.73)           | 0.0929 | 1.86                | (1.05–3.29)           | 0.0343 | 34    |

HR = hazard ratio; 95% CI = 95% confidence interval. * P<0.10 was considered significant in univariate Cox regression analysis; ** P<0.05 was considered significant in multivariate Cox regression analysis.
Clinical performance of the nomogram

DCA is a novel evaluation tool for clinical net benefit of prediction models. The DCA curves of the nomogram and FIGO staging system for 3- and 5-year OS are presented in Figure 6. The wider range of threshold probabilities of the nomogram suggest a superior net benefit in comparison to FIGO stage.

Discussion

SCSTs are uncommon and heterogeneous, with favorable prognosis, but slow progression of the tumor can cause relapse, and there is no accepted standard approach [17]. Due to its rarity, there is little information to guide clinical decision-making and prognosis prediction. In addition, the efficacy of chemotherapy for FIGO stage IC and advanced patients is controversial. Long-term chemotherapy can cause irreversible and severe toxicity resulting from the cumulative dose effect [18]. Hence, the present study was designed to build a more comprehensive prognostic model and to consider the effect of chemotherapy in different stages.

Currently, nomograms are broadly used as prognostic tools to generate individual probabilities by integrating multiple predictors, which connect biological and clinical characteristics [19]. To the best of our knowledge, no previous studies have established nomograms for postoperative sex cord-stromal tumors, probably due to the small number of patients. Our SEER-based nomogram includes parameters that are clinically practical and

Table 4. Comparison of prognostic effect between nomogram and FIGO staging system.

| Cox model   | C-index* (95%CI) | C-index** (95%CI) | C-index*** (95%CI) |
|-------------|-----------------|------------------|-------------------|
| Nomogram    | 0.850 (0.805, 0.895) | 0.786 (0.696, 0.876) | 0.768 (0.717, 0.819) |
| FIGO        | 0.710 (0.644, 0.776) | 0.583 (0.477, 0.689) | 0.668 (0.610, 0.726) |

* Comparison of C-index in the training set; ** comparison of C-index in the validation set; *** comparison of C-index in the overall population.
stromal tumors are needed to verify our results.

Further studies on sex cord-serum levels can be used to monitor response to chemotherapy. Previous research has demonstrated that CA125 is an established prognostic marker of epithelial ovarian cancer, regardless of disease stage, but its effect on SCSTs has not been elucidated. In the present study, the increased CA125 levels were found in patients with advanced disease, but its value for early-stage SCSTs patients was not investigated. The nomogram shows that advanced FIGO stage of disease and elevated CA125 levels are the most important factors contributing to poor prognosis. Multiple studies have shown that stage matters most [7,20,21], as stage I–II patients had 36% better survival than advanced patients [10]. CA125 is an established prognostic marker of epithelial ovarian cancer, regardless of disease stage, but its effect on SCSTs has not been elucidated. In the present study, the increased CA125 levels in patients did not influence the prognosis of their long duration or their high malignancy [27]. It has been reported that smaller tumor size indicates low probability of recurrence [28] and better survival [27]. Another SEER-based study, by Zhang et al., found that patients with well differentiated and moderately differentiated SCSTs had better 5-year survival than those with poorly differentiated tumors [10].

The nomogram shows that advanced FIGO stage of disease and elevated CA125 levels are the most important factors contributing to poor prognosis. Multiple studies have shown that stage matters most [7,20,21], as stage I–II patients had 36% better survival than advanced patients [10]. CA125 is an established prognostic marker of epithelial ovarian cancer, regardless of disease stage, but its effect on SCSTs has not been elucidated. In the present study, the increased CA125 levels in patients did not influence the prognosis of their long duration or their high malignancy [27]. It has been reported that smaller tumor size indicates low probability of recurrence [28] and better survival [27]. Another SEER-based study, by Zhang et al., found that patients with well differentiated and moderately differentiated SCSTs had better 5-year survival than those with poorly differentiated tumors [10].

We found that unmarried status was associated with worse overall survival in SCSTs patients. Although no previous study on SCSTs has investigated it, many studies on ovarian cancer have shown that unmarried women have an higher risk than married women, especially for those who are widowed or separated/divorced [29,30]. Although this predictive factor could

![ROC curves](image)

**Figure 3.** ROC curves of the nomogram and FIGO stage for 1-, 3-, and 5-year overall survival (OS) in (A) training set and (B) internal validation set. ROC – receiver operating characteristic; AUC – area under the curve.

We found that age ≤50 years, tumor size ≤95 mm, and high degree of differentiation are independent predictors for improved survival, in agreement with previous studies [10,24,25]. Younger age is usually associated with better physical status and intensive treatment, which may explain this difference [26]. Sex cord-stromal tumors can grow to large size, either because of their long duration or their high malignancy [27]. It has been reported that smaller tumor size indicates low probability of recurrence [28] and better survival [27]. Another SEER-based study, by Zhang et al., found that patients with well differentiated and moderately differentiated SCSTs had better 5-year survival than those with poorly differentiated tumors [10].

We found that unmarried status was associated with worse overall survival in SCSTs patients. Although no previous study on SCSTs has investigated it, many studies on ovarian cancer have shown that unmarried women have a higher risk than married women, especially for those who are widowed or separated/divorced [29,30]. Although this predictive factor could...
Figure 4. The calibration curves predicting 1-, 3-, and 5-year overall survival (OS) in (A) training set and (B) internal validation set.
be confounded by emotional and economic support, it should still be considered in clinical practice.

At present, there is no consensus on use of adjuvant chemotherapy after surgery. Generally, it is suggested it be reserved for advanced-stage and recurrent disease [6]. Rupture of ovarian tumors has been identified as a negative prognostic predictor [31]; therefore, FIGO stage IC patients are also advised to receive chemotherapy. After using propensity score matching to control other confounders, multivariate analysis showed that the general effect of chemotherapy for the overall population was deleterious. Survival curves of specific stages displayed no difference in OS in FIGO stage III groups, which is consistent with the results of Badawi et al. [32] This is possibly because SCSTs tend to generate resistance to chemotherapy and have high recurrence rates. It may also due to the preselection of patients or ineffective chemotherapeutic regimens. In addition, multiple studies have found that patients with stage I and II disease did not benefit from postoperative chemotherapy, even if they had high-risk characteristics [34,35].

This finding suggests that surgery is sufficient for indolent early-stage cancer, and that chemotherapy can impair quality of life by serious adverse effects. Several single-nucleotide polymorphisms could be used to identify patients who are more likely to experience cisplatin-related toxicities [18]. Interestingly, even stage IA patients can experience relapse after administration of chemotherapy [36]. Since valid evidence on its benefit is still inadequate, individualized assessment and subsequent counseling should be provided before making clinical decisions.

Generally speaking, our study has several innovative advantages. This study is based on a large cohort of patients from 18 registries, and thus minimizes the selection and surveillance biases and allowed us to reach reliable conclusions. To better investigate the disputed effect of chemotherapy, we conducted propensity score matching to eliminate other confounding factors such as age, grade, histology, tumor size, and CA125 levels. Chemotherapy in current clinical practice is based on FIGO stages, so the stratification of chemotherapy is
Figure 5. Overall survival (OS) of SCST patients who underwent surgery. Kaplan-Meier survival curve for patients with sex cord-stromal tumors. (A) Patients grouped by median value of prognostic index (PI) according to FIGO stages. Red lines represent low-risk groups, green lines represent high-risk groups. (B, C) Patients at different FIGO stages stratified by whether they received chemotherapy or not. Red lines represent patients without or unknown if received chemotherapy, green lines represent patients who received chemotherapy.
naturally associated with significant difference in FIGO stages, even after PSM. To the best of our knowledge, this is the first study on sex cord-stromal tumors to provide a survival prediction model in the form of a nomogram, which has natural convenience in clinical application. The predictive factors in our study are practical and readily available. We also propose that CA125 levels and marital status should be taken into clinical consideration in subsequent SCST research. The results of DCA shows that our integrated nomogram has superior clinical utility compared to the FIGO staging system in prognosis prediction.

With regard to the research methods, some limitations need to be acknowledged. Firstly, our data was extracted from the SEER database, and the retrospective design has inherent deficiencies. The long span of study time entails changes in treatments and histopathologic evaluation. In addition, several important factors are unavailable from the SEER database, including gravidity, parity, chemotherapy regimen, extent of residual tumors, recurrence, performance status, and mitotic index. As chemotherapy protocols differ among different medical institutions, data from multi-institutional settings are required to determine the optimal scheme. Information on

Figure 6. Decision curve analysis for nomogram and FIGO stage. The nomogram was compared to FIGO stage model in regard to 3- (left) and 5-year (right) overall survival (A) in the overall study population, (B) in the training set, and (C) in the validation set. The y-axis represents net benefit while the x-axis stands for the threshold probability. “All” refers to the assumption that all patients reached the endpoint and “none” to the hypothesis that no patients reached the endpoint.

You D. et al.: Prognostic prediction model of sex cord-stromal tumor patients
© Med Sci Monit, 2020; 26: e925844

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
ascites is largely unavailable, although about half of patients with Sertoli-Leydig cell tumors present with abdominal symptoms due to ascites [37]. Further studies on external validation or reliable indicators are required to build a more accurate prediction model. The lack of clear benefit from chemotherapy also calls for the development of targeted medication for SCSTs.

Conclusions

We developed an individualized nomogram that can predict OS of postoperative patients with sex cord-stromal tumors. The training set and validation set exhibited good discrimination and calibration and better clinical utility than FIGO stage. We found that chemotherapy provided the reverse effect for overall stages, and further investigation should be carried out to confirm this finding. In spite of its limitations, this study offers some insights that may help prognosis evaluation and clinical decision-making.

Acknowledgements

The authors thank the Surveillance, Epidemiology, and End-Results (SEER) program for providing open access to the SEER database.

Conflict of Interest

None.

References:

1. Colombo N, Parma G, Zanagnolo V, Inzinga A: Management of ovarian stromal cell tumors. J Clin Oncol, 2007; 25(20): 2944–51
2. Gatta G, van der Zwan IM, Casali PG et al: Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer, 2011; 47(17): 2493–511
3. Young RH: Sex cord-stromal tumors of the ovary and testis: Their similarities and differences with consideration of selected problems. Mod Pathol, 2005; 18(Suppl. 2): S81–98
4. Ray-Coquard I, Brown J, Harter P et al: Gynecologic Cancer Inter Group (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer, 2014; 24(9 Suppl. 3): 542–47
5. Boussios S, Moschetta M, Zarikavelis G et al: Ovarian sex-cord stromal tumors and small cell tumors: Pathological, genetic and management aspects. Crit Rev Oncol Hematol, 2017; 120: 43–51
6. Mangili G, Sigismondi C, Frigerio L et al: Recurrent granulosa cell tumors (GCTs) of the ovary: A MITO-9 retrospective study. Gynecol Oncol, 2013; 130(1): 38–42
7. Evans AT, Gaffey TA, Malkasian GD, Annegers JF: Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol, 1980; 55(2): 231–38
8. Schneider DT, Calaminus G, Wessalowski R et al: Ovarian sex cord – stromal tumors in children and adolescents. J Clin Oncol, 2003; 21(12): 2357–63
9. Boussios S, Zarikavelis G, Seraj E et al: Non-epithelial ovarian cancer: Elucidating uncommon gynaecological malignancies. Anticancer Res, 2016; 36(10): 5031–42
10. Zhang M, Cheung MK, Shin JY et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary – an analysis of 376 women. Gynecol Oncol, 2007; 104(2): 396–400
11. Cronin KA, Ries LA, Edwards BK: The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer, 2014; 120(Suppl. 23): 3755–57
12. Dabi Y, Huchon C, Ouldamer L et al: Patients with stage IV epithelial ovarian cancer: Understanding the determinants of survival. J Transl Med, 2020; 18(1): 134
13. Collins GS, Reitsma JB, Altman DG et al: Transparent reporting of a multi-variable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. The TRIPOD Group. Circulation, 2015; 131(2): 211–19
14. Rosenbaum PR, Rubin DB: Reducing bias in observational studies using sub-classification on the propensity score. Journal of the American Statistical Association, 1984; 79(387): 516–24
15. Chappell LC, Allotey J, Fernandez-Felix BM et al: Predicting seizures in pregnant women with epilepsy: Development and external validation of a prognostic model. PLoS Med, 2019; 16(5): e1002802
16. Vickers AJ, Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Medical Decis Making, 2016; 26(6): 565–74
17. Koulouris CR, Pensom RT: Ovarian stromal and germ cell tumors. Semin Oncol, 2009; 36(2): 126–36
18. Boussios S, Mikropoulos C, Samartzis E et al: Wise management of ovarian cancer: On the cutting edge. J Pers Med, 2020; 10(2): e41
19. Balachandran VP, Gonen M, Smith J, DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet Oncol, 2015; 16(4): e173–80
20. Björkhomel E, Silfverswärd C: Prognostic factors in granulosa – cell tumors. Gynecol Oncol, 1981; 11(3): 261–74
21. Malmstrom H, Hogberg T, Risberg B, Simonsen E: Granulosa cell tumors of the ovary: Prognostic factors and outcome. Gynecol Oncol, 1994; 52(1): 50–55
22. Nasioudis D, Wilson E, Mastroymannis SA, Latif NA: Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage I ovarian sex cord-stromal tumors. Eur J Obstet Gynecol Reprod Biol, 2019; 238: 86–89
23. Gupta D, Lis CG: Role of CA125 in predicting ovarian cancer survival – a review of the epidemiological literature. J Ovarian Res, 2009; 2: 13
24. Chan JK, Zhang M, Kaleb V et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary – a multivariate analysis. Gynecol Oncol, 2005; 96(1): 204–9
25. Stenwig JT, Hazekamp JT, Beecham JB: Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol, 1979; 7(2): 136–52
26. Chan, J, Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol, 2003; 102(1): 156–61
27. Fox H, Agrawal K, Langley FA: A clinicopathological study of 92 cases of granulosa cell tumors of the ovary. The Journal of Obstetrics and Gynaecology of the Commonwealth, 2005; 18(Suppl. 2): S81–98
28. Miller BE, Barron BA, Van JF et al: Prognostic factors in adult granulosa cell tumor of the ovary. Cancer, 1997; 79(10): 2311–55
29. Peres LC, Sinha S, Townsend MK et al: Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecol Oncol, 2020; 156(2): 459–66
30. Trudel-Fitzgerald C, Poole EM, Sood AK et al: Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study. Psychosom Med, 2019; 81(9): 833–40
31. Wilson MK, Fong P, Mesnage S et al: Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecol Oncol, 2015; 138(2): 285–91
32. Al-Badawi IA, Brasier PM, Ghatage P et al: Postoperative chemotherapy in advanced ovarian granulosa cell tumors. Int J Gynecol Cancer, 2002; 12(1): 119–23
33. Brown J, Brady WE, Schink J et al: Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group. Cancer, 2014; 120(3): 344–51

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
34. Nasioudis D, Ko EM, Haggerty AF et al: Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors. Gynecol Oncol Rep, 2019; 28: 145–48
35. Nasioudis D, Orfanelli T, Frey MK et al: Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors. J Gynecol Oncol, 2019; 30(2): e19
36. Weng CS, Chen MY, Wang TY et al: Sertoli-Leydig cell tumors of the ovary: A Taiwanese Gynecologic Oncology Group study. Taiwan J Obstet Gynecol, 2013; 52(1): 66–70
37. Zanotti K: The clinical manifestations and diagnosis of Sertoli-Leydig cell tumors of the ovary. J Gynecol Oncol, 2002; 7: 129–33